The USP28 antibody is a tool used to study the ubiquitin-specific protease 28 (USP28), a deubiquitinating enzyme involved in regulating protein stability and cellular processes. USP28 belongs to the ubiquitin-specific protease family, which cleaves ubiquitin chains from substrate proteins, counteracting ubiquitin-mediated degradation. It plays a critical role in DNA damage response, cell cycle regulation, and apoptosis by stabilizing key proteins such as c-Myc, p53. and Claspin. USP28 interacts with components of the Fanconi anemia (FA) pathway and the COP9 signalosome, highlighting its involvement in genomic stability and cancer biology.
Research has linked USP28 to cancer progression, where it can act as both an oncogene and tumor suppressor, depending on cellular context. Overexpression of USP28 is observed in certain cancers, such as colorectal and lung cancer, where it promotes cell proliferation by stabilizing oncoproteins like c-Myc. Conversely, USP28 also participates in tumor suppression by stabilizing p53 under stress conditions. This dual functionality makes USP28 a complex therapeutic target.
Antibodies against USP28 are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect protein expression, localization, and interactions. They are essential for studying USP28’s regulatory mechanisms, post-translational modifications, and roles in disease models. Specificity and validation (e.g., knockout controls) are critical due to structural similarities among USP family members. These antibodies aid in exploring USP28’s potential as a biomarker or drug target in cancer and other pathologies.